Asparaginase is an antineoplastic enzyme used in the treatment of acute lymphoblastic leukemia (ALL), with a remission rate exceeding 50%; it is also effective against acute myeloid leukemia, acute monocytic leukemia, and malignant lymphoma, including cases relapsed after conventional therapy; it exhibits no cross-resistance with commonly used agents such as mercaptopurine, vincristine, cytarabine, or methotrexate; additionally, it is used for managing leukopenia, thrombocytopenia, and aplastic anemia caused by various conditions.